By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
enGenes Biotech Brings Its E. coli Toolbox to BIO-Europe 2026
Vienna, Austria: – enGenes Biotech to meet partners on the NorthX Biologics booth in Cologne, 9–11 November.
Got a protein that won’t express? enGenes Biotech wants to hear about it at BIO-Europe 2026.
The recombinant proteins and plasmid DNA specialist CDMO will join the booth of its partner NorthX Biologics, the Swedish GMP CDMO, at Koelnmesse, Cologne, from 9 to 11 November. Business Development Manager Ophelia Gevaert will be on hand to meet companies looking for a partner in recombinant protein, peptide and plasmid DNA production.
“BIO-Europe is where developers bring their toughest production problems, and that’s exactly where our E. coli platform shines,” said Ophelia Gevaert, Business Development Manager at enGenes Biotech. “Whether it’s a hard-to-express protein, a cell-toxic molecule or plasmid DNA at scale, we want to hear about it in Cologne.”
Five Technologies, One Workhorse Host
At the core of enGenes’ offer is a family of E. coli expression technologies, each built to solve a specific production headache:
-eXpress™ decouples cell growth from recombinant expression, delivering higher yields, tighter process control and access to hard-to-express proteins.
-eXtra™ secretes products directly into the medium, ideal for cell-toxic molecules and simpler downstream processing.
-eXpand™ incorporates non-canonical amino acids, opening up new protein functionality, immobilisation and click chemistry.
-eXcess™ produces plasmid DNA at high density for scalable manufacturing and better process economics.
-eXchange™ enables antibiotic-free production to support regulatory compliance.
From Strain to Scale
Behind the technologies sits a full development service. enGenes tailors E. coli production strains to challenging proteins, peptides and plasmid DNA. It then combines high-throughput screening with bioreactor development to move projects from proof of concept to scalable production.
Product-specific downstream processing ensures efficient recovery and consistent quality. And for clients chasing productivity, enGenes runs E. coli production continuously for extended periods, cutting the manufacturing footprint.
Ready-to-Use Bioprocessing Products
Visitors can also learn about two enGenes products:
Affinity ligands: recombinant protein A ligands for efficient antibody capture and resin development.
eXrase™: a Serratia marcescens nuclease for efficient nucleic acid removal in bioprocessing and downstream purification.
A Familiar Face in Cologne
enGenes is a BIO-Europe regular, and Gevaert also represented the company at the 2025 edition.
Book a meeting
Pre-schedule a one-to-one with Ophelia Gevaert through the BIO-Europe partnering app, or drop by the NorthX Biologics booth during the event.
About enGenes Biotech
enGenes Biotech is an Austrian biotechnology company developing advanced microbial expression technologies for the production of recombinant proteins, peptides, and plasmid DNA.
Founded in 2014 and headquartered in Vienna, enGenes has built a portfolio of proprietary E. coli-based platform technologies that enable high-performance recombinant production, extracellular secretion, continuous biomanufacturing, and scalable bioprocessing. These technologies help biotechnology companies overcome production bottlenecks, improve process economics, and accelerate product development.
Leveraging its technology platform, enGenes provides bioprocess development and manufacturing services spanning strain engineering, upstream and downstream process development, and contract manufacturing. In parallel, the company is expanding a portfolio of recombinant bioprocessing products, including affinity ligands and nucleases that support next-generation biomanufacturing workflows.
enGenes serves customers across biopharma, diagnostics, industrial biotechnology, food technology, and synthetic biology worldwide.
Find out more at: https://www.engenes.cc
About BIO-Europe
BIO-Europe is one of Europe’s largest biotech partnering events, now in its 32nd year. The 2026 edition takes place 9–11 November at Koelnmesse, Cologne, Germany, bringing together more than 6,000 senior leaders from biotech, pharma, investment and strategic organisations across Europe, North America and Asia. Attendees book one-to-one meetings in advance through the partneringONE platform, making the event a key venue for licensing, collaboration and investment deals.
BIO-Europe is organised by Informa Connect, part of Informa PLC. informaconnect.com/bioeurope
Resources
Contact enGenes to arrange a meeting at World Vaccine Congress Europe.
Related Articles
